Table 1.
Baseline demographics and clinical characteristics
| Patient characteristics | n = 49 |
|---|---|
| Male | 36 (73) |
| Median (IQR) age (y) | 52 (41–59) |
| Median (IQR) age of onset of psoriasis (y) | 24 (16–40) |
| Median (IQR) disease duration (y) | 22 (14–28) |
| Median (IQR) BMI (kg m–²) | 27·4 (25·1–30·1) |
| Smoker | 13 (27) |
| Psoriatic arthritis | 11 (22) |
| Previous biological | 35 (71) |
| Concomitant methotrexate | 6 (12) |
| Median (IQR) absolute PASI baseline | 18·6 (14·8–22·5) |
| Median (IQR) treatment duration ustekinumab (wks) | 74 (28–129) |
| Ustekinumab dosage 90 mg | 18 (37) |
Data are n (%) unless otherwise indicated. IQR, interquartile range; y, years; BMI, body mass index; PASI, Psoriasis Area Severity Index.